Mitoxantrone: a novel anthracycline derivative - PubMed

Affiliations

• PMID: 3048848

Review

Mitoxantrone: a novel anthracycline derivative

J Koeller et al. Clin Pharm. 1988 Aug.

Abstract

The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and adverse effects of mitoxantrone are reviewed. Mitoxantrone, an aminoanthraquinone that was synthesized in 1979, belongs to a new chemical class of agents known as the anthracenediones. It possesses antiviral, antibacterial, immunomodulatory, and antitumor activity. The drug's antitumor activity is attributed to its interaction with DNA topoisomerase II, and its interaction with human cells may also involve nonintercalary, electrostatic interactions. Mitoxantrone is poorly absorbed orally and is most commonly administered intravenously. The drug is rapidly distributed into the red blood cells, white blood cells, and platelets, followed by deep-tissue sequestration. Mitoxantrone has demonstrated clinical efficacy in the treatment of leukemia, lymphoma, and breast cancer. As a single agent, mitoxantrone has a response rate of roughly 30% in acute nonlymphocytic leukemia or acute myeloid leukemia. In combination with other standard agents (cytarabine, vincristine, and prednisone), the response rate may reach 60%. In breast cancer, mitoxantrone's response rate as a single agent is 25-30%, while combination regimens produce response rates of 60% or more. The drug can cause cardiotoxicity with cumulative doses. Other adverse effects include myelosuppression, nausea and vomiting, stomatitis, mucositis, and alopecia. The cost of mitoxantrone is comparable to that of doxorubicin, but it is substantially more expensive than daunorubicin. Mitoxantrone is an important new agent with antitumor activity in leukemia, lymphoma, and breast cancer. In most situations, mitoxantrone will be considered second-line treatment or a restricted-use item because of its high cost and because of the lack of FDA approval for indications other than acute nonlymphocytic leukemia.

Similar articles

• Mitoxantrone: bluebeard for malignancies.

  van der Graaf WT, de Vries EG. van der Graaf WT, et al. Anticancer Drugs. 1990 Dec;1(2):109-25. Anticancer Drugs. 1990. PMID: 2151849

• [Introduction of a new anticancer drug, novantrone].

  Tsukagoshi S. Tsukagoshi S. Gan To Kagaku Ryoho. 1987 Nov;14(11):3163-72. Gan To Kagaku Ryoho. 1987. PMID: 3314715 Clinical Trial. Japanese.

• Idarubicin: an anthracycline antineoplastic agent.

  Cersosimo RJ. Cersosimo RJ. Clin Pharm. 1992 Feb;11(2):152-67. Clin Pharm. 1992. PMID: 1551297 Review.

• Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.

  Greco FA, Hainsworth JD. Greco FA, et al. Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-61-S17-64. Semin Oncol. 1997. PMID: 9374096 Clinical Trial.

Cited by

• Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.

  Senkal M, Tonn JC, Schönmayr R, Schachenmayr W, Eickhoff U, Kemen M, Kollig E. Senkal M, et al. J Neurooncol. 1997 May;32(3):203-8. doi: 10.1023/a:1005792410604. J Neurooncol. 1997. PMID: 9049881

• Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

  Minond D, Saldanha SA, Subramaniam P, Spaargaren M, Spicer T, Fotsing JR, Weide T, Fokin VV, Sharpless KB, Galleni M, Bebrone C, Lassaux P, Hodder P. Minond D, et al. Bioorg Med Chem. 2009 Jul 15;17(14):5027-37. doi: 10.1016/j.bmc.2009.05.070. Epub 2009 Jun 22. Bioorg Med Chem. 2009. PMID: 19553129 Free PMC article.

• Potentiation of cytotoxicity of mitoxantrone toward CHO-K1 cells in vitro by dipyridamole.

  Desai PB, Sridhar R. Desai PB, et al. Pharm Res. 1992 Feb;9(2):178-81. doi: 10.1023/a:1018920903436. Pharm Res. 1992. PMID: 1553337

• Antineoplastic drugs in 1990. A review (Part II).

  Black DJ, Livingston RB. Black DJ, et al. Drugs. 1990 May;39(5):652-73. doi: 10.2165/00003495-199039050-00003. Drugs. 1990. PMID: 2191847 Review. No abstract available.

• Indium/Gallium Maltolate Effects on Human Breast Carcinoma Cells: In Vitro Investigation on Cytotoxicity and Synergism with Mitoxantrone.

  Merli D, Profumo A, Bloise N, Risi G, Momentè S, Cucca L, Visai L. Merli D, et al. ACS Omega. 2018 Apr 30;3(4):4631-4640. doi: 10.1021/acsomega.7b02026. Epub 2018 Apr 26. ACS Omega. 2018. PMID: 30023897 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program